Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.62 USD | -3.33% | -0.44% | -24.52% |
05-10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
05-10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.52% | 2.12B | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Needham Adjusts Price Target on Rocket Pharmaceuticals to $60 From $62, Maintains Buy Rating